Novocure has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the use of its portable Optune Lua device alongside PD-1/PD-L1 inhibitors to treat non-small cell lung ...
Optune Lua adoption lag hit shares, but 2026 catalysts and $230M net cash could drive a rebound. Know more about NVCR stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback